| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 12/06/2024 | 21:55 | GlobeNewswire Inc. | CORRECTION-- Science 37 Surpasses Enrollment Goals, Accelerates Phase 2 Rare Disease Clinical Trial | NASDAQ:SNCE | Science 37 Holdings Inc |
| 12/06/2024 | 14:00 | GlobeNewswire Inc. | Science 37 Surpasses Enrollment Goals, Accelerates Phase 2 Rare Disease Clinical Trial | NASDAQ:SNCE | Science 37 Holdings Inc |
| 13/05/2024 | 14:00 | GlobeNewswire Inc. | Science 37 Metasite™ Undergoes Successful FDA Inspection, Marking Major Milestone in Virtual Site Quality Assurance and Compliance | NASDAQ:SNCE | Science 37 Holdings Inc |
| 09/05/2024 | 16:00 | GlobeNewswire Inc. | Science 37 Wins 2024 MedTech Breakthrough Award for “Clinical Efficiency Innovation” | NASDAQ:SNCE | Science 37 Holdings Inc |
| 02/05/2024 | 14:00 | GlobeNewswire Inc. | Science 37 Delivers 22x Faster Enrollment than Traditional Methods in Phase 3 Asthma Clinical Trial | NASDAQ:SNCE | Science 37 Holdings Inc |
| 17/04/2024 | 14:00 | GlobeNewswire Inc. | Science 37 Provides Fully Consented Patients to Sites to Supplement Enrollment | NASDAQ:SNCE | Science 37 Holdings Inc |
| 12/03/2024 | 11:45 | PR Newswire (US) | eMed completes tender offer for all outstanding shares of Science 37 | NASDAQ:SNCE | Science 37 Holdings Inc |
| 04/03/2024 | 12:18 | Edgar (US Regulatory) | Form SC TO-T/A - Tender offer statement by Third Party: [Amend] | NASDAQ:SNCE | Science 37 Holdings Inc |
| 04/03/2024 | 12:01 | Edgar (US Regulatory) | Form SC 14D9/A - Solicitation, recommendation statements: [Amend] | NASDAQ:SNCE | Science 37 Holdings Inc |
| 20/02/2024 | 05:16 | PR Newswire (US) | Kuehn Law Encourages DFS, SNCE, HRT, and IONM Investors to Contact Law Firm | NASDAQ:SNCE | Science 37 Holdings Inc |
| 12/02/2024 | 15:03 | Edgar (US Regulatory) | Form SC 14D9 - Solicitation, recommendation statements | NASDAQ:SNCE | Science 37 Holdings Inc |
| 12/02/2024 | 14:16 | Edgar (US Regulatory) | Form SC TO-T - Tender offer statement by Third Party | NASDAQ:SNCE | Science 37 Holdings Inc |
| 12/02/2024 | 13:45 | PR Newswire (US) | eMed commences tender offer for Science 37 | NASDAQ:SNCE | Science 37 Holdings Inc |
| 09/02/2024 | 13:49 | Edgar (US Regulatory) | Form SC14D9C - Written communication relating to third party tender offer | NASDAQ:SNCE | Science 37 Holdings Inc |
| 09/02/2024 | 13:40 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:SNCE | Science 37 Holdings Inc |
| 30/01/2024 | 16:11 | Edgar (US Regulatory) | Form SC TO-C - Written communication relating to an issuer or third party | NASDAQ:SNCE | Science 37 Holdings Inc |
| 12/12/2023 | 14:00 | GlobeNewswire Inc. | Science 37 Receives Top Honors in Everest PEAK Matrix® | NASDAQ:SNCE | Science 37 Holdings Inc |
| 07/12/2023 | 22:59 | GlobeNewswire Inc. | Science 37 Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) | NASDAQ:SNCE | Science 37 Holdings Inc |
| 05/12/2023 | 13:00 | GlobeNewswire Inc. | Science 37 Holdings, Inc. Announces 1-for-20 Reverse Stock Split effective December 8, 2023 | NASDAQ:SNCE | Science 37 Holdings Inc |
| 07/11/2023 | 12:39 | Edgar (US Regulatory) | Form S-8 - Securities to be offered to employees in employee benefit plans | NASDAQ:SNCE | Science 37 Holdings Inc |
| 07/11/2023 | 12:04 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:SNCE | Science 37 Holdings Inc |
| 27/10/2023 | 22:11 | Edgar (US Regulatory) | Form DEF 14A - Other definitive proxy statements | NASDAQ:SNCE | Science 37 Holdings Inc |
| 10/10/2023 | 22:16 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:SNCE | Science 37 Holdings Inc |
| 03/10/2023 | 22:15 | Edgar (US Regulatory) | Form PRE 14A - Other preliminary proxy statements | NASDAQ:SNCE | Science 37 Holdings Inc |
| 20/09/2023 | 13:59 | GlobeNewswire Inc. | Science 37 Chief Delivery Officer, Darcy Forman, Named to Prestigious PharmaVoice 100 List | NASDAQ:SNCE | Science 37 Holdings Inc |
| 13/09/2023 | 13:59 | GlobeNewswire Inc. | Science 37 Recognized in the Gartner® Hype Cycle™ for Life Science Clinical Development, 2023 | NASDAQ:SNCE | Science 37 Holdings Inc |
| 12/09/2023 | 13:59 | GlobeNewswire Inc. | Science 37 Named Market Leader for Global Decentralized Clinical Trials by Frost & Sullivan | NASDAQ:SNCE | Science 37 Holdings Inc |
| 15/08/2023 | 13:59 | GlobeNewswire Inc. | Science 37 Recognized as Best Digital Health Solution Nominee at 2023 Prix Galien USA Awards | NASDAQ:SNCE | Science 37 Holdings Inc |
| 11/07/2023 | 13:59 | GlobeNewswire Inc. | Synlogic Partners with Science 37 on Pivotal Study for Investigational Drug for Phenylketonuria (PKU) | NASDAQ:SNCE | Science 37 Holdings Inc |
| 27/06/2023 | 22:45 | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:SNCE | Science 37 Holdings Inc |